Blog

Johnson & Johnson Discontinues Late-Stage Study of Bladder Cancer Drug TAR-200 Following Lack of Efficacy

Hannah Perry | October 8, 2024

Johnson & Johnson Halts Late-Stage Study for Bladder Cancer Drug TAR-200 In a significant development within the pharmaceutical industry, Johnson & Johnson (J&J) announced on Monday that it has decided to discontinue a late-stage clinical trial assessing its experimental drug, TAR-200, for the treatment of muscle-invasive bladder cancer (MIBC). The decision comes as the experimental…

Hims & Hers Health Stock: Navigating Volatility Amidst Weight-Loss Drug Market Changes

Hannah Perry | October 4, 2024

The Volatile Market Dynamics of Hims & Hers Health Stock Amid Weight-Loss Drug Developments Introduction to Hims & Hers Health Hims & Hers Health has witnessed a rollercoaster of stock performance in recent months, primarily due to its strategic pivot into the weight-loss drug market. After launching its weight-loss offerings, the company’s stock value surged…

Weight-Loss Revolution: How Compounding Pharmacies are Changing the GLP-1 Drug Landscape

Hannah Perry | October 3, 2024

Weight-Loss Drugs: The Rise of GLP-1 Copycats The Proliferation of Compounding Pharmacies In recent months, the availability of weight-loss drugs like Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy has surged, largely thanks to copycat versions produced by compounding pharmacies. These alternative options have become as easy to purchase as the latest tech gadgets, often advertised…

IGM Biosciences Stock Takes 14% Dive Following Strategic Shift to Autoimmune Diseases and Leadership Changes

Hannah Perry | October 2, 2024

IGM Biosciences Stock Plummets After Strategic Shift to Autoimmune Diseases In a surprising move, IGM Biosciences Inc. saw its stock plunge by 14% on Tuesday following the announcement of a major strategic pivot. The company, which had previously focused its efforts on oncology, is now shifting its attention toward autoimmune diseases—a transition that has left…

3 High-Yield Dividend Stocks to Buy Now for Income Stability

Hannah Perry | October 1, 2024

3 Dividend Stocks Yielding 5% To 11% To Scoop Up Now In a volatile market, investors often seek safe harbors for their capital. Dividend stocks typically emerge as a reliable option, providing consistent and regular income contrary to the often erratic performance of growth stocks. While growth stocks can generate significant returns over an extended…

Best Pharma Stock to Invest $1,000 in Now: Eli Lilly’s Promising Future

Hannah Perry | September 30, 2024

This Is the Best Pharma Stock to Invest $1,000 in Right Now Eli Lilly (NYSE: LLY) has emerged as a frontrunner in the pharmaceutical sector, demonstrating a robust performance that shows no signs of faltering. With its highly successful drug lines focusing on type 2 diabetes and weight loss just beginning to penetrate global markets,…

Eli Lilly Stock Analysis: Is It Time to Buy After Ebglyss FDA Approval?

Hannah Perry | September 27, 2024

Is Eli Lilly Stock a Buy After Winning FDA Approval for Ebglyss? Eli Lilly (LLY) stock has been tracking sideways as of late September after the company received Food and Drug Administration (FDA) approval for its new eczema drug, Ebglyss. This groundbreaking treatment is aimed at individuals aged 12 and older suffering from moderate-to-severe eczema…

Bristol-Myers Squibb: A Top Dividend Giant with Low Short Interest in 2024

Hannah Perry | September 26, 2024

Bristol-Myers Squibb Company (BMY): Among the Dividend Giants with Lowest Short Interest in 2024 Introduction to Short Selling and Market Trends Recently, our analysis has spotlighted **Bristol-Myers Squibb Company (NYSE:BMY)** as a player among Dividend Giants with the lowest short interest rates in 2024. This comes in the wake of ongoing challenges faced by short…

Novo Nordisk CEO Under Fire Over Ozempic and Wegovy Pricing Strategies Amid Rising Drug Costs

Hannah Perry | September 25, 2024

Novo Nordisk CEO Faces Scrutiny Over Ozempic and Wegovy Pricing Addressing Lawmakers on Capitol Hill The CEO of Novo Nordisk, Lars Jorgensen, recently appeared before lawmakers on Capitol Hill to defend the pricing strategies of the company’s blockbuster diabetes and obesity medications, Ozempic and Wegovy. During the hearing, Sen. Bernie Sanders, the chair of the…

UCB’s Bimzelx Secures FDA Approvals: A Game-Changer in Psoriasis and Immunology Treatment

Hannah Perry | September 24, 2024

UCB’s Bimzelx: A Triumphant Surge in FDA Approvals Enhancing Blockbuster Potential Celebrated biopharmaceutical company UCB is rapidly elevating the prospects of its psoriasis treatment, Bimzelx (also known as bimekizumab), following a series of significant endorsements from the U.S. Food and Drug Administration (FDA). In a remarkable stride for the pharmaceutical giant, Bimzelx garnered three vital…

« Previous PageNext Page »